Smart nanoparticles, which can respond to biological cues or be guided by them, are
emerging as a promising drug delivery platform for precise cancer treatment. The field of …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

The great clinical success of cisplatin and its derivatives has convinced people that metal
complexes could play a more significant role in human cancer therapy. However, targeting …

Organoid models have the potential to recapitulate the biological and pharmacotypic
features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis …

Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited
efficacy of single agents. The design and testing of combinations are however very …

The concept of synthetic lethality has been widely applied to identify therapeutic targets in
cancer, with varying degrees of success. The standard approach normally involves …

Patient-derived organoids (PDOs) can model personalized therapy responses; however,
current screening technologies cannot reveal drug response mechanisms or how tumor …

Pancreatic cancer is a highly malignant and incurable disease, characterized by its
aggressive nature and high fatality rate. The most common type is pancreatic ductal …

Melanoma represents the most fatal form of skin cancer due to its resistance mechanisms
and high capacity for the development of metastases. Among other medicinal techniques …

The identification of the priority control sequence of pollutants in effluents of wastewater
treatment plants (WWTPs) has important implications for the management of water quality …